Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia (VenBom)
VenBom: A Phase 1 Study of Bomedemstat (IMG-7289), a Novel Inhibitor of Lysine-Specific Demethylase 1 (LSD1), in Combination With Venetoclax in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Listed as NCT05597306, this PHASE1 trial focuses on Acute Myeloid Leukemia and Acute Myeloid Leukemia, in Relapse and remains actively recruiting participants. Sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA), it has been updated 9 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
Jan 2025 — Feb 2026 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Jul 2023 — Dec 2023 [monthly]
Recruiting PHASE1
-
Jan 2023 — Jul 2023 [monthly]
Recruiting PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Nov 2022 — Dec 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
- Terrence J Bradley, MD
For direct contact, visit the study record on ClinicalTrials.gov .